September 25, 2010  4:30 – 6:00 PM Chicago, IL

Join us for this FREE 1½ hour educational and networking event for aplastic anemia patients and their family members.

Registration is NOW OPEN.

Learn about new and exciting developments in the treatment of aplastic anemia from Dr. Phillip Scheinberg, a physician and researcher at the National Heart, Lung and Blood Institute, National Institutes of Health. Dr. Scheinberg specializes in treating patients' bone marrow failure disorders including those with aplastic anemia. Plenty of time will be provided to answer your questions and to meet and talk to other patients and their families.

NOTE: Pre-registration is required to attend this free event.

When:

Saturday, September 25, 2010 from 4:30 – 6:00 PM. On site check-in will begin at 4:00 PM and doors will open at 4:15 PM. Drinks and snacks will be provided.

Where: 

Wyndham Chicago
633 North St. Clair Street
Chicago, IL 60611
(312) 573-0300

The meeting will be held in the Grand Ballroom, second floor.

View hotel directions .

If you need assistance with registration, please call (877) 295-5620 or (507) 288-5620 and ask for the registrar. Be sure to identify this as the Aplastic Anemia Update - Chicago.

PARKING: Plenty of hotel parking is available. Participants receive a special day rate of $12 for day parking and $29 for overnight parking.

Agenda

4:00 PM	Registration table opens
4:30 - 4:45 PM	Introduction	Paul Scribner, MSW Aplastic Anemia & MDS International Foundation
4:45 - 5:30 PM	Understanding New and Emerging Therapies	Philip Scheinberg, MD National Institutes of Health
5:30 - 5:45 PM	Questions and Answers
5:45 - 6:00 PM	Mix and Mingle

More About the Presenter:

Dr. Phillip Scheinberg is a staff clinician at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, MD. He is currently involved in clinical protocols in bone marrow failure syndromes such as aplastic anemia, myelodysplastic syndromes and large granular lymphocytic leukemia. The focus of these protocols is to investigate novel immunosuppressive regimens that will improve the response rate in untreated severe aplastic anemia (SAA) and prevent relapses and clonal evolution to myelodysplastic syndromes. In patients with SAA who are not responsive to initial anti-thymocyte globulin (ATG) and cyclosporine, protocols are being developed to improve the success of salvage therapies with repeat immunosuppressive therapy. Dr. Scheinberg received an MD Degree in 1995 in Sao Paulo, Brazil, completed an internship and residency at Mount Sinai Medical Center in Miami Beach, FL from 1997 to 2001 and a Hematology/Oncology Fellowship at the Hematology Branch of NHLBI from 2001to 2005.